An Open-Label Phase 2 Study of INCB050465 in Participants With Primary Sjögren’s Syndrome

https://www.clinicaltrials.gov/ct2/show/NCT03627065 A Study of INCB050465 in Primary Sjögren’s Syndrome Brief Summary: The purpose of this study is to assess the impact of parsaclisib on the signs and symptoms of Sjögren’s syndrome (SS). Condition or disease Intervention/treatment Phase Primary Sjögren’s Syndrome Drug: Parsaclisib Phase 2 Study Design Go to sections Study Type : Interventional Estimated Enrollment […]